medigraphic.com
Academia Mexicana de Neurología, A.C.

2016, Number 1

<< Back Next >>

Rev Mex Neuroci 2016; 17 (1)

Neurocognitive and neuropsychiatric features of Parkinson disease

Seubert-Ravelo AN, Yáñez-Téllez MG

Language: Spanish
References: 50
Page: 65-75
PDF size: 143.24 Kb.


ABSTRACT

Parkinson disease (PD) is considered a movement disorder; nonetheless its current conception includes a series of non-motor symptoms comprising neurocognitive and neuropsychiatric symptoms. The objective of the present review is to offer an updated perspective of PD associated cognitive and psychiatric symptoms. The spectrum of cognitive dysfunction includes mild cognitive impairment and PD associated dementia, while the most common psychiatric symptoms include depression, anxiety, apathy, psychosis and impulse control disorders. The neurobiological base of cognitive and psychiatric features in PD involves dysfunction of corticosubcortical circuitry, as well as different neurotransmitter systems, especially monoaminergic and cholinergic systems. Cognitive and psychiatric features in PD have a relevant detrimental effect in the quality of life of patients and caregivers. Furthermore, the presence of such symptoms makes PD treatment a complex matter, in some cases restricting therapeutic options; timely identification and management in therefore relevant.


REFERENCES

  1. Parkinson J. An essay on the shaking palsy. Vol 14. London: Whittingham y Rowland for Sherwood, Neeley and Jones, 1817.

  2. Chaudhuri KR, Schapira AH V. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8:464-474.

  3. Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci 2006; 248:151-157.

  4. Elgh E, Domellöf M, Linder J, Edström M, Stenlund H, Forsgren L. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol 2009; 16:1278-1284.

  5. McKinlay A, Grace RC, Dalrymple-Alford JC, Roger D. Characteristics of executive function impairment in Parkinson’s disease patients without dementia. J Int Neuropsychol Soc 2010;16:268- 277.

  6. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004; 17:195-200.

  7. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22:1689-1707.

  8. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27:349- 356.

  9. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 2000; 100:285-290.

  10. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord 2014; 29:634-650.

  11. Rinne JO, Rummukainen J, Paljärvi L, Säkö E, Mölsä P, Rinne UK. Neuronal loss in the substantia nigra in patients with Alzheimer’s disease and Parkinson’s disease in relation to extrapyramidal symptoms and dementia. Prog Clin Biol Res 1989; 317:325-332.

  12. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp Neurol 1997; 144:202-213.

  13. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry 2013; 84:774-783.

  14. Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol 1984; 64:43-52.

  15. Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997; 244:2-8.

  16. Zgaljardic DJ, Borod JC, Foldi NS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson’s disease. J Clin Exp Neuropsychol 2006; 28:1127-1144.

  17. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006; 253:242-247.

  18. Pedersen KF, Larsen JP, Tysnes O-B, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013; 70:580-586.

  19. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75:1062-1069.

  20. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837-844.

  21. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-1720.

  22. Higginson CI, Wheelock VL, Carroll KE, Sigvardt KA. Recognition memory in Parkinson’s disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J Clin Exp Neuropsychol 2005; 27:516-528.

  23. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67:492-496.

  24. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21:148-158.

  25. Veazey C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2005; 17:310-323.

  26. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study 1. Parkinson J. An essay on the shaking palsy. Vol 14. London: Whittingham y Rowland for Sherwood, Neeley and Jones, 1817. 2. Chaudhuri KR, Schapira AH V. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8:464-474. 3. Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci 2006; 248:151-157. 4. Elgh E, Domellöf M, Linder J, Edström M, Stenlund H, Forsgren L. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol 2009; 16:1278-1284. 5. McKinlay A, Grace RC, Dalrymple-Alford JC, Roger D. Characteristics of executive function impairment in Parkinson’s disease patients without dementia. J Int Neuropsychol Soc 2010;16:268- 277. 6. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004; 17:195-200. 7. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22:1689-1707. 8. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27:349- 356. 9. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 2000; 100:285-290. 10. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord 2014; 29:634-650. 11. Rinne JO, Rummukainen J, Paljärvi L, Säkö E, Mölsä P, Rinne UK. Neuronal loss in the substantia nigra in patients with Alzheimer’s disease and Parkinson’s disease in relation to extrapyramidal symptoms and dementia. Prog Clin Biol Res 1989; 317:325-332. 12. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp Neurol 1997; 144:202-213. 13. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry 2013; 84:774-783. 14. Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol 1984; 64:43-52. 15. Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997; 244:2-8. 16. Zgaljardic DJ, Borod JC, Foldi NS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson’s disease. J Clin Exp Neuropsychol 2006; 28:1127-1144. 17. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006; 253:242-247. 18. Pedersen KF, Larsen JP, Tysnes O-B, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013; 70:580-586. 19. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75:1062-1069. 20. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837-844. 21. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-1720. 22. Higginson CI, Wheelock VL, Carroll KE, Sigvardt KA. Recognition memory in Parkinson’s disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J Clin Exp Neuropsychol 2005; 27:516-528. 23. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67:492-496. 24. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21:148-158. 25. Veazey C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2005; 17:310-323. 26. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study1. Parkinson J. An essay on the shaking palsy. Vol 14. London: Whittingham y Rowland for Sherwood, Neeley and Jones, 1817. 2. Chaudhuri KR, Schapira AH V. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8:464-474. 3. Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci 2006; 248:151-157. 4. Elgh E, Domellöf M, Linder J, Edström M, Stenlund H, Forsgren L. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol 2009; 16:1278-1284. 5. McKinlay A, Grace RC, Dalrymple-Alford JC, Roger D. Characteristics of executive function impairment in Parkinson’s disease patients without dementia. J Int Neuropsychol Soc 2010;16:268- 277. 6. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004; 17:195-200. 7. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22:1689-1707. 8. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27:349- 356. 9. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 2000; 100:285-290. 10. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord 2014; 29:634-650. 11. Rinne JO, Rummukainen J, Paljärvi L, Säkö E, Mölsä P, Rinne UK. Neuronal loss in the substantia nigra in patients with Alzheimer’s disease and Parkinson’s disease in relation to extrapyramidal symptoms and dementia. Prog Clin Biol Res 1989; 317:325-332. 12. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp Neurol 1997; 144:202-213. 13. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry 2013; 84:774-783. 14. Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol 1984; 64:43-52. 15. Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997; 244:2-8. 16. Zgaljardic DJ, Borod JC, Foldi NS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson’s disease. J Clin Exp Neuropsychol 2006; 28:1127-1144. 17. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006; 253:242-247. 18. Pedersen KF, Larsen JP, Tysnes O-B, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013; 70:580-586. 19. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75:1062-1069. 20. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837-844. 21. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-1720. 22. Higginson CI, Wheelock VL, Carroll KE, Sigvardt KA. Recognition memory in Parkinson’s disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J Clin Exp Neuropsychol 2005; 27:516-528. 23. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67:492-496. 24. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21:148-158. 25. Veazey C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2005; 17:310-323. 26. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55:377-382.

  27. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson’s disease? Psychol Med 2001; 31:65-73.

  28. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.

  29. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 1991; 50:743-755.

  30. Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease. BMC Psychiatry 2014; 14:19.

  31. Quelhas R, Costa M. Anxiety, depression, and quality of life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2009; 21:413-419.

  32. Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Mov Disord 2009; 24:1333-1338.

  33. Siemers ER, Shekhar A, Quaid K, Dickson H. Anxiety and motor performance in Parkinson’s disease. Mov Disord 1993; 8:501-506.

  34. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 2009; 24:2175-2186.

  35. Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73:636- 642.

  36. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson’s disease. Mov Disord 2007; 22:778-784.

  37. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease: Prevalence, phenomenology and risk factors. Brain 2000;123:733-745.

  38. Marsh L. Psychosis in Parkinson ’ s Disease. Prim Psychiatry 2005;12:56-62.

  39. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson ’ s disease. J Neurol Neurosurg Psychiatry 2001; 70:734-738.

  40. Wolters EC. Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 1999; 52:S10-S13.

  41. Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010; 25:1399-1408.

  42. Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson’s disease. Brain 2009; 132:2350-2355.

  43. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a crosssectional study of 3090 patients. Arch Neurol 2010; 67:589-595.

  44. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65:1570-1574.

  45. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM- IV. 4th Ed. Arlington: American Psychiatric Press Inc, 1994.

  46. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-- control study. Ann Neurol 2011; 69:986-996.

  47. Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol 2011; 24:324-330.

  48. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 2008; 23:75-80.

  49. Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68:423-428..

  50. Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 2014; 85:311-318




2020     |     www.medigraphic.com